For the millions of people who live with vitiligo, a disease that robs the
skin of its natural color, a newly approved cream called ruxolitinib
(Opzelura) is quickly becoming a game changer.
skin of its natural color, a newly approved cream called ruxolitinib
(Opzelura) is quickly becoming a game changer.
The U.S. Food and Drug Administration approved ruxolitinib for vitiligo in
people aged 12 and older in July. The drug, part of a class known as Janus
kinase (JAK) inhibitors, targets JAK, a molecule involved in the
development and progression of vitiligo.
About half of folks with vitiligo who used the cream got 75% or more
pigment back on the face and 50% or more pigment back on their whole body
after a year of use, the study found. More than one-third of adults and
more than 50% of adolescents in the study said their vitiligo was no longer
noticeable or a lot less noticeable after a year.
